scholarly journals Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations

2011 ◽  
Vol 19 (5) ◽  
pp. 500-506 ◽  
Author(s):  
Claire Julian-Reynier ◽  
Julien Mancini ◽  
Emmanuelle Mouret-Fourme ◽  
Marion Gauthier-Villars ◽  
Valérie Bonadona ◽  
...  
2013 ◽  
Vol 85 (1) ◽  
pp. 49-53 ◽  
Author(s):  
T Pal ◽  
J-H Lee ◽  
A Besharat ◽  
Z Thompson ◽  
ANA Monteiro ◽  
...  

2019 ◽  
Vol 152 (3) ◽  
pp. 514-521 ◽  
Author(s):  
Charlotte C. Sun ◽  
Larissa A. Meyer ◽  
Molly S. Daniels ◽  
Diane C. Bodurka ◽  
Denise R. Nebgen ◽  
...  

2005 ◽  
Vol 23 (36) ◽  
pp. 9319-9328 ◽  
Author(s):  
Katrina Armstrong ◽  
Barbara Weber ◽  
Peter A. Ubel ◽  
Nikki Peters ◽  
John Holmes ◽  
...  

Purpose Women with BRCA1/2 mutations are faced with complex decisions about breast and ovarian cancer risk management. This study was conducted to determine the effect of a tailored decision support system (DSS) that provides individualized survival and cancer incidence curves specific to expected outcomes of alternative management strategies. Patients and Methods This was a double-blind, randomized controlled trial of 32 women with BRCA1/2 mutations. Primary outcome measures were decision satisfaction, cancer anxiety, perceptions of cancer risk given alternative management strategies, and management decisions. Results Twenty-seven women completed a 6-week follow-up. Women in the intervention arm (n = 13) reported significantly higher decision satisfaction at follow-up than women in the control arm (n = 14; adjusted mean difference, 9.7; P < .0005). The effect of the DSS was greater among women with low cancer anxiety at baseline than women with high cancer anxiety at baseline (P = .01 for interaction). However, the DSS did not significantly alter cancer anxiety at follow-up, perceptions of cancer risk given alternative management strategies, or management decisions. Conclusion The presentation of individualized survival and incidence curves for alternative management options improves satisfaction about cancer risk management decisions among women with BRCA1/2 mutations without increasing anxiety or changing management decisions. The benefit of the DSS is greatest among women with relatively low cancer-related anxiety at baseline.


BMJ Open ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. e045075
Author(s):  
Sarah A McGarrigle ◽  
Geraldine Prizeman ◽  
Carol Spillane ◽  
Niamh Byrne ◽  
Amanda Drury ◽  
...  

IntroductionWomen who inherit a pathogenic mutation in Breast Cancer Susceptibility Genes 1 or 2 (BRCA1 or BRCA2) are at substantially higher risk of developing breast and ovarian cancer than the average woman. Several cancer risk management strategies exist to address this increased risk. Decisions about which risk management strategies to choose are complex, personal and multifactorial for these women. This scoping review will map evidence relevant to cancer risk management decision making in BRCA mutation carriers without a personal history of cancer. The objective is to identify and describe the features of patient decision aids that have been developed for BRCA mutation carriers. This information may be beneficial for designing new decision aids or adapting existing decision aids to support decision making in this population.Methods and analysisThis scoping review will be conducted according to the Joanna Briggs Institute’s scoping review methodological framework. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist will be used for guidance. Studies on decision aids for women with a BRCA mutation who are unaffected by breast or ovarian cancer will be considered for inclusion. Five electronic databases will be searched (MEDLINE, EMBASE, Cochrane Library, CINAHL, Web of Science) with no restrictions applied for language or publication date. Studies for inclusion will be selected independently by two review authors. Data will be extracted using a predefined data extraction form. Findings will be presented in tabular form. A narrative description of the evidence will complement the tabulated results.Ethics and disseminationEthical approval for conducting this scoping review is not required as this study will involve secondary analysis of existing literature. Findings will be published in a peer-reviewed journal and presented at relevant conferences.


2011 ◽  
Vol 13 (2) ◽  
pp. 148-154 ◽  
Author(s):  
Sharon E Plon ◽  
H Paul Cooper ◽  
Bethany Parks ◽  
Shweta U Dhar ◽  
P Adam Kelly ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document